IN
InvestingNurse
Community Contributor
Member since 2025
Views
275 Total number of views
Fair Values Set
4 Total number of fair values set
Comments
0 Total number of comments
Followers
0 Total number of followers
No bio added yet
No link added
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more
IN
US$5
79.4% undervalued intrinsic discount
Fair Value
Profit Margin
13.44%
Future PE
24.75x
Price in 2031
US$7.33
Lexaria Bioscience's Breakthrough with DehydraTECH to Revolutionize Drug Delivery
Lexaria Bioscience is testing multiple drug agents using their DehydraTECH (DHT) technology for oral and topical delivery of medications such as GLP-1and CBD. The DehydraTECH is showing substantial improvement in bioabsorption, brain permeation, taste maksing, and side effect reduction.Read more
IN
US$5.55
87.6% undervalued intrinsic discount
Fair Value
Profit Margin
15.26%
Future PE
22.75x
Price in 2031
US$7.65